TABLE 5.
Risk Factors for GF and Mortality After Re-LT in Patients With PSC
| GF
|
Mortality
|
|||
|---|---|---|---|---|
| Univariate HR (95% CI) |
Multivariate HR (95% CI) |
Univariate HR (95% CI) |
Multivariate HR (95% CI) |
|
| At 30 days | ||||
| Re-LT for REC | 0.47 (0.25–0.87) | 0.36 (0.17–0.77) | ||
| Re-LT for PNF | 2.19 (1.36–3.52) | 2.28 (1.35–3.83) | ||
| Contemporary era* | 0.59 (0.37–0.93) | 0.54 (0.32–0.89) | ||
| Time to re-LT | ||||
| 0–7 days | Reference | Reference | ||
| 8–30 days | 0.45 (0.20–0.98) | 0.41 (0.18–0.95) | ||
| >30 days | 0.40 (0.21–0.73) | 0.35 (0.18–0.66) | ||
| In ICU | 2.36 (1.50–3.71) | 2.72 (1.65–4.48) | ||
| Mechanical ventilation | 3.39 (2.12–5.41) | 2.97 (1.85–4.78) | 4.07 (2.46–6.74) | 3.97 (2.36–6.67) |
| Total bilirubin | 1.02 (1.00–1.03) | 1.02 (1.00–1.04) | ||
| Creatinine | 1.36 (1.20–1.54) | 1.30 (1.14–1.48) | 1.37 (1.19–1.57) | 1.34 (1.15–1.56) |
| Albumin† | 0.68 (0.48–0.98) | 0.60 (0.42–0.87) | ||
| Donor age ≥ 60 years | 2.01 (1.09–3.73) | 2.28 (1.19–4.38) | ||
| At 5 years | ||||
| Re-LT for REC | 0.56 (0.40–0.80) | 0.62 (0.43–0.90) | 0.47 (0.32–0.70) | 0.54 (0.36–0.82) |
| Re-LT for PNF | 1.58 (1.16–2.15) | 1.49 (1.06–2.10) | ||
| Contemporary era* | 0.60 (0.46–0.80) | 0.68 (0.51–0.91) | 0.58 (0.43–0.79) | 0.69 (0.50–0.95) |
| Time to re-LT | ||||
| 0–7 days | Reference | Reference | ||
| 8–30 days | 0.53 (0.32–0.89) | 0.54 (0.31–0.92) | ||
| >30 days | 0.51 (0.34–0.77) | 0.48 (0.31–0.76) | ||
| In ICU | 1.71 (1.29–2.26) | 1.83 (1.36–2.48) | ||
| Mechanical ventilation | 2.07 (1.51–2.84) | 1.64 (1.18–2.28) | 2.12 (1.51–2.99) | 1.60 (1.12–2.28) |
| Total bilirubin | 1.02 (1.01–1.03) | 1.02 (1.01–1.02) | 1.02 (1.01–1.03) | 1.02 (1.01–1.03) |
| Creatinine | 1.22 (1.12–1.33) | 1.18 (1.08–1.30) | 1.21 (1.10–1.33) | 1.15 (1.04–1.28) |
| Living donor‡ | 3.03 (1.34–6.82) | 5.74 (2.49–13.22) | ||
| Donor age ≥ 60 years | 2.00 (1.36–2.94) | 1.94 (1.31–2.87) | 2.12 (1.41–3.20) | 2.01 (1.33–3.04) |
NOTE: Only covariates significant (P < 0.05) in univariate analyses and included in multivariate models are shown. Nonsignificant covariates included the following: age, sex, race/ethnicity, IBD diagnosis, UNOS region, primary liver malignancy, DCD donor, split graft, other indications for re-LT, and number of causes of GF.
*
Transplants performed from 2005 to 2015 versus 1987 to 2004.
†
Nonsignificant in univariate analysis of 30-day GF.
‡
Nonsignificant in univariate analysis of 5-year mortality.